A 16-week intervention with the PPARγ-agonist rosiglitazone has proven to increase myocardial glucose uptake during a hyperinsulinemic euglycemic clamp in both ischemic and non-ischemic regions in individuals with T2DM and coronary artery disease [66], showing that myocardial glucose uptake can not only be affected by bariatric surgery or lifestyle adjustments but also by drugs. Here, PPARG is linked to type 2 diabetes mellitus.